Home › Funds › Siren, L.L.C. › RLAY
Siren, L.L.C. position in RLAY
Relay Therapeutics, Inc. · Health Care
Siren, L.L.C. reported holding 3,262,976 shares of RLAY (Relay Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$58.9M, representing 1.40% of its reported portfolio and ranking #21 among its reported holdings. Siren, L.L.C. has disclosed RLAY holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s RLAY position evolved
Siren, L.L.C. first disclosed a stake in RLAY in Q2 2026 at 3,650,000 shares (US$68.3M). Across 2 filings, Siren, L.L.C. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,262,976 shares valued at US$58.9M — a reduction of -387,024 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 3.65M | $68.29M | New |
| Q3 2026 | 3.26M | $58.90M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RLAY and 13F data
RLAY (Relay Therapeutics, Inc.) is a Health Care company. 64 other funds we track also report a position in RLAY — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$522.1M), Casdin Capital (US$300.0M), PERCEPTIVE ADVISORS LLC (US$263.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLAY
- SB INVESTMENT ADVISERS (UK) LTD 27.90M sh · $522.10M · Q2 2026
- Casdin Capital 16.04M sh · $300.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 14.11M sh · $263.93M · Q2 2026
- Commodore Capital LP 12.00M sh · $224.52M · Q2 2026
- Nextech Invest Ltd. 6.78M sh · $126.79M · Q2 2026
- Bellevue Group AG 6.19M sh · $115.74M · Q2 2026
- TCG Crossover Management, LLC 4.27M sh · $79.95M · Q2 2026
- Kynam Capital Management, LP 3.30M sh · $61.74M · Q2 2026
- Spruce Street Capital LP 2.98M sh · $55.83M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $52.89M · Q2 2026
- MPM BioImpact LLC 2.42M sh · $45.20M · Q2 2026
- Elmind Capital, LP 1.47M sh · $27.42M · Q2 2026
More on Siren, L.L.C.
FAQ
How long has Siren, L.L.C. held RLAY?
Siren, L.L.C. has disclosed RLAY holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Siren, L.L.C.'s current position in RLAY?
As of Q3 2026, Siren, L.L.C. holds 3.26M shares of RLAY (Relay Therapeutics, Inc.), valued at $58.90M, representing 1.40% of its reported portfolio and ranking #21.
Has Siren, L.L.C. been buying or selling RLAY?
In the latest 13F filing (Q3 2026), Siren, L.L.C. reduced its position in RLAY.
Which other funds hold RLAY?
Other major institutional holders of RLAY include SB INVESTMENT ADVISERS (UK) LTD, Casdin Capital, PERCEPTIVE ADVISORS LLC, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.